R(+)PPX High Dose Treatment of ALS

Completed · Phase 1/Phase 2

Conditions studied: Amyotrophic Lateral Sclerosis

In brief

R(+)pramipexole is administered in escalating doses to patients with early ALS. Plasma and spinal fluid levels of R(+)PPX are monitored, in addition to biochemical markers of oxidative stress.

Key facts

Study ID

NCT00600873

Run by

Bennett, James P., Jr., M.D., Ph.D.

People needed

10

Starts

2007-08-01

Expected to finish

2009-01-01

Last updated by the study team

2010-09-13

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• definite ALS no prior exposure to R(+)PPX

You may not qualify if…

• ALSFRS at baseline <40 FVC at baseline <70%

Where it is running

• University of Virginia — Charlottesville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.